Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tofacitinib · 1 trial · 1 indication
Number of participants with presence and size of induration in active versus control at the Candin injection site compared to the intra-individual saline control injection site approximately 48 hours after Candin challenge will be reported.
| Arm | Type | Description |
|---|---|---|
| Candin + Tofacitinib | EXPERIMENTAL | Participants will receive a single dose of Candin injection on forearm of 1 arm along with a saline solution injection of 0.9 percent (%) sodium chloride (NaCl) on the opposite forearm on Day 3 and oral dose of tofacitinib for 5 days. |
| Candin Challenge | NO_INTERVENTION | All participants will receive a single dose of Candin injection on forearm of 1 arm along with a saline solution injection of 0.9% NaCl on the opposite forearm on Day 3. |
| Name | Type | Description |
|---|---|---|
| Tofacitinib | DRUG | Tofacitinib tablet will be administered orally. |
Inclusion Criteria: * Have a body mass index (BMI) between 18 and 30 kilograms per meter square (kg/m\^2) (BMI = weight/height\^2), inclusive, and a body weight of no less than 50 kilograms (kg) * Healthy on the basis of physical examination, medical history, and vital signs performed at screening....
Tofacitinib is a small molecule drug being developed by Johnson & Johnson (JNJ). It is currently in Phase 1 clinical development. The drug is being studied in healthy participants, and its therapeutic area is classified as Other.
Tofacitinib is being studied for use in healthy participants. It is currently in Phase 1 clinical development, with one completed trial involving 12 participants. The drug is not yet approved and is still in the investigational stage.
Tofacitinib is being developed by Johnson & Johnson, which trades under the ticker JNJ. The company is conducting clinical trials to evaluate the drug in healthy participants.
Tofacitinib is in Phase 1 clinical development. It is an investigational drug and has not been approved. One Phase 1 trial has been completed, with no active trials currently ongoing.
Tofacitinib has one completed clinical trial, NCT04985955, titled "A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3." This Phase 1 trial enrolled 12 participants in Belgium and was not double-blinded.
Tofacitinib is the drug name provided in the data. No alternative names have been listed for this drug in the available information.